Extensive HCP Access and Research Coverage Across IBD, Liver Disease, Hepatitis, and Gastrointestinal Disorders
Konovo’s Gastroenterology Therapeutic Breakdown delivers comprehensive insights into global market research capabilities within gastrointestinal and liver health. Over the past three years, we have completed 425 projects and collected 26,178 respondent completes from a verified panel of over 2 million healthcare professionals, including gastroenterologists, hepatologists, and internal medicine specialists. Our research covers a wide range of conditions—such as Crohn’s disease, ulcerative colitis, irritable bowel syndrome, celiac disease, eosinophilic esophagitis, hepatitis B and C, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and gastroesophageal reflux. Supported by rigorous quality controls and proprietary recruitment technologies, Konovo ensures high-quality, representative data to help pharmaceutical, biotech, and medtech companies make faster, evidence-based decisions in the gastroenterology market.
